Rhythm Pharmaceuticals (RYTM) Common Equity (2016 - 2026)

Rhythm Pharmaceuticals (RYTM) has 11 years of Common Equity data on file, last reported at $122.9 million in Q1 2026.

• On a quarterly basis, Common Equity rose 548.68% year-over-year to $122.9 million in Q1 2026; TTM through Mar 2026 was $122.9 million, a 548.68% increase from a year earlier, with the FY2025 full-year figure at $139.1 million, up 540.02% from the prior year.
• Common Equity for Q1 2026 stood at $122.9 million, down from $139.1 million in the prior quarter.
• Over the last five years, Common Equity for RYTM reached as high as $281.2 million in Q3 2022 and fell as low as -$11.9 million in Q2 2025.
• Historically, Common Equity has averaged $135.2 million across 5 years, with a median of $148.8 million in 2025.
• On a YoY basis, Common Equity climbed as much as 1226.95% in 2025 and fell as far as 130.27% in 2025.
• Year by year, Common Equity stood at $264.3 million in 2022, then plunged by 35.76% to $169.8 million in 2023, then sank by 87.2% to $21.7 million in 2024, then jumped by 540.02% to $139.1 million in 2025, then declined by 11.62% to $122.9 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $122.9 million in Q1 2026, $139.1 million in Q4 2025, and $148.8 million in Q3 2025.